Evotec SE (EVO)
|Net Income (ttm)||136.62M|
|Day's Range||22.29 - 23.35|
|52-Week Range||20.90 - 24.36|
|Earnings Date||Nov 18, 2021|
Evotec is an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry. In order to address demand for faster, cheaper and better outcomes of early-stage drug discovery processes, we deliver fully-integrated drug discovery and development programs to our partners. Our expertise in deep learning and computational approaches and the integration of such knowledge across the full value chain of research, drug discovery and development is industry-leading. We possess capabilities across the early stage... [Read more...]
In 2020, Evotec SE's revenue was 500.92 million, an increase of 12.20% compared to the previous year's 446.44 million. Earnings were 6.25 million, a decrease of -83.58%.Financial numbers in millions EURFinancial Statements
CAMBRIDGE, Mass. & HAMBURG, Germany--(BUSINESS WIRE)--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and...
EQRX TO LEVERAGE EVOTEC'S UNIQUE DATA-DRIVEN INTEGRATED DRUG DISCOVERY AND DEVELOPMENT ACCELERATOR PLATFORM PARTNERSHIP AIMS TO BUILD UP JOINTLY OWNED PIPELINE TO DELIVER INNOVATIVE, AFFORDABLE AND ACCE...
STRONG OPERATIONAL PERFORMANCE LEADS TO SIGNIFICANT REVENUE GROWTH CO-OWNED PIPELINE GAINING MOMENTUM J.POD (R) REDMOND (US) OPERATIONAL SUCCESSFUL PUBLIC OFFERING AT NASDAQ (AFTER PERIOD-END) GUIDANCE ...
THE DESIGNATION OF ADDITIONAL PROGRAMMES BY BRISTOL MYERS SQUIBB TRIGGERED PAYMENTS OF IN TOTAL US$ 40 M TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / November 10, 2021 / Evotec SE (Frankfurt Stock Exchange...
HAMBURG, GERMANY / ACCESSWIRE / November 9, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today the closing of its public offering on 08 Novembe...
Evotec, which provides drug discovery solutions for the pharmaceutical industry, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Evotec SE has filed to go public with an IPO on the NASDAQ.
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its collaboration with Bristol Myers Squibb (NYSE: BMY) has been expanded to include a new cell type, trig...